Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

A Patch for Peanut Allergies

By Drug Discovery Trends Editor | April 9, 2015

Viaskin® patch. (Source: DBV Technologies)French biopharmaceutical company DBV Technologies moves closer to bringing its peanut allergy patch to market, receiving Breakthrough Therapy Designation from the U.S. Food and Drug Administration as it prepares to launch its Phase 3 trial. 

The circular patch, called Viaskin Peanut, delivers peanut protein directly onto the superficial layers of the skin so that it is slowly administered into the immune system, but does not pass into the bloodstream.  By avoiding the bloodstream, the therapy has been shown to significantly reduce the chance of anaphylactic shock from peanut exposure in children across ages.  The worst side effects in clinical Phase 2 trials were localized rashes, according to the company.  

The patch could prevent anaphylactic shock if someone with a peanut allergy were to accidentally eat something with traces of peanuts, or an amount roughly equivalent to four peanuts, according to a company representative.

 “We are truly honored to be the first company to receive this FDA designation in food allergies,” Dr. Pierre-Henri Benhamou, M.D., Chairman and CEO of DBV Technologies said. “This is an historical event for the peanut allergy patients, caretakers and clinicians that have long awaited for a treatment for this severe disease.”

The Breakthrough Therapy designation, which is intended to expedite the development and review of drugs/biological products that target serious or life-threatening conditions, is specifically for the treatment of peanut allergies in children, from toddlers to teenagers. A Breakthrough Therapy drug must show preliminary clinical evidence of a substantial improvement on a clinically significant endpoint over available therapies, or over placebo if there is no available therapy.

While still a couple of years away from commercial development, the therapy has promise for the potentially life-threatening disease, and was granted a Fast Track designation from the FDA in December of 2011.

DBV Technologies is also developing a patch for milk allergies and a treatment for dust mites.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE